Q3 2024 EPS Estimates for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Reduced by Analyst

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) – Equities research analysts at HC Wainwright dropped their Q3 2024 earnings per share estimates for shares of Oramed Pharmaceuticals in a research note issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.04) per share for the quarter, […]

Related Keywords

, Hedge Funds Weigh In On Oramed Pharmaceuticals , Algert Global , News Ratings For Oramed Pharmaceuticals Daily , Oramed Pharmaceuticals Inc , Oramed Pharmaceuticals Stock Performance , Rathbones Group , Nasdaq , Oramed Pharmaceuticals , Ew Advisory Services , Barclays Plc , Capital Management , Free Report , Oramed Pharmaceutical , Get Free Report , Advisory Services , Pharmaceuticals Inc , Oramed Pharmaceuticals Daily ,